Ultrasound-guided radiofrequency ablation for the treatment of papillary thyroid carcinoma: a review of the current state and future perspectives

Article information

Ultrasonography. 2024;43(2):79-87
Publication date (electronic) : 2023 December 11
doi : https://doi.org/10.14366/usg.23091
1Department of Ultrasound, First Medical Center, Chinese PLA General Hospital, Beijing, China
2Department of Ultrasound, Air Force Medical Center, Beijing, China
Correspondence to: Ming-bo Zhang, MD, Department of Ultrasound, First Medical Center, Chinese PLA General Hospital, No. 28, Fuxing Road, Haidian District, Beijing 100853, China Tel. +86-13552744805 Fax. +86-010-66937394 E-mail: owsifanduizhe@126.com
Received 2023 May 15; Revised 2023 December 1; Accepted 2023 December 11.


Papillary thyroid carcinoma (PTC) is a highly prevalent cancer that typically exhibits indolent behavior and is associated with a favorable prognosis. The treatment of choice is surgical intervention; however, this approach carries the risk of complications, including scarring and loss of thyroid function. Although active surveillance can mitigate the risk of PTC overtreatment, the possibility of tumor growth and metastasis can elicit anxiety among patients. Ultrasound-guided thermal ablation has emerged as a safe and effective alternative for individuals who are ineligible for or decline surgery. This article provides a review of the clinical research on radiofrequency ablation as a treatment for PTC, offering a thorough examination of its efficacy, safety, and future perspectives.


Thyroid cancer is the most common endocrine malignancy [1,2]. Papillary thyroid carcinoma (PTC) represents approximately 80% of all thyroid cancer cases [3] and is typically characterized by its indolent nature and favorable prognosis. Current guidelines [4-7] primarily recommend surgical intervention as the treatment of choice for PTC. However, surgery can lead to complications, such as permanent recurrent laryngeal nerve injury, hypoparathyroidism, scarring, and hypothyroidism necessitating thyroxine replacement therapy. These conditions may persist for a lifetime and can reduce patients’ quality of life [8,9]. To avoid overtreatment of PTC, active surveillance (AS) has been recommended [10]; however, some patients may prefer an alternative. Notably, the choice to perform delayed surgery during AS is often driven by patient anxiety regarding the possibility of tumor growth and metastasis [11-14]. Accordingly, research is exploring less invasive alternatives to surgery beyond AS for the management of PTC.

Increasing attention has been paid to the application of thermal ablation [15] for the treatment of PTC. This minimally invasive approach requires precise placement, which is facilitated by real-time, high-frequency ultrasound (US) guidance [5]. Various percutaneous thermal ablation technologies are commercially available, including radiofrequency ablation (RFA), microwave ablation, laser ablation, and high-intensity focused US [16]. Of these, RFA is a widely adopted method for PTC treatment [17]. Accordingly, the goal of the present article was to review the clinical research pertaining to RFA in the context of PTC and to comprehensively examine its efficacy, safety, and perspectives. This review is intended to serve as a resource to support clinical decision-making regarding PTC treatment.

Evaluation of the Principle, Procedures, and Efficacy of RFA

Principle of RFA

The fundamental mechanism of RFA involves employing a high-frequency alternating current, with wavelengths between 200 and 1,200 kHz, to create an oscillating electric field. As a result, polar macromolecules and charged ions in the tissue adjacent to the electrode needle are driven to vibrate at high speeds, generating frictional heat. Once the temperature reaches 60°C, the affected tissues undergo coagulation necrosis, carbonization, dehydration, and irreversible damage [18]. This process leads to a decrease in tissue volume and ultimately to the absorption of the ablated region [19].

Procedure of RFA

When considering RFA, multidisciplinary consultation should be utilized if available. RFA is recommended for patients who are ineligible for or who decline surgery and AS. Prior to RFA, patients should undergo US examination, computed tomography (CT), US-guided fine-needle aspiration or core needle biopsy, and laboratory examination. Routine US is used to assess the size and location of the tumor, its US characteristics, and its vascularity. CT scans of the neck and chest are conducted to identify any lymph node (LN) involvement or distant metastases. Biopsy samples are analyzed via cytopathological or histopathological evaluation, as well as for the presence of the BRAFV600E mutation. Finally, laboratory tests include assessments of thyroid function and blood coagulation [8].

During RFA, the patient is placed in the supine position with the shoulders properly cushioned and the head tilted back to fully expose the neck. Multi-section US scanning is performed to assess the anatomical relationship between the tumor and the adjacent tissues. Based on this assessment, the RFA protocol is tailored to the tumor’s size and location. Following routine disinfection, 1% lidocaine hydrochloride is applied to the tissue, with US guidance employed to isolate the skin puncture site from the anterior boundary of the thyroid gland. To safeguard critical structures such as the trachea, common carotid artery, and recurrent laryngeal nerve from thermal injury, a protective liquid barrier is created. This is achieved by injecting a suitable volume of liquid—normal saline, 5% glucose, or lidocaine [20]—into the neck’s natural anatomical spaces around the thyroid gland. This injection forms a 5- to 10-mm protective zone that temporarily separates the tumor from these vital structures [21,22]. Next, a safe puncture route is chosen, and an electrode needle is positioned within the tumor under real-time US guidance for the ablation procedure. For larger tumors, the moving-shot technique is employed [23]. This involves segmenting the tumor into multiple small ablation units and then performing edge-overlapping ablation on each unit. In this process, the heat source is moved to avoid thermal damage to nearby tissues and to ensure complete ablation of the tumor. For small tumors, the electrode needle is inserted into the center of the tumor and remains stationary throughout the ablation. During ablation, clinicians should closely monitor vital signs, such as heart rate, blood pressure, and oxygen saturation.

The duration of ablation, as well as the power and energy settings, are determined based on the size and composition of the tumor [24]. For bipolar electrodes, the power is typically set between 3 and 5 W [25,26], whereas other RFA modalities may utilize a higher power, reaching up to 20 W [27]. It is advisable to perform contrast-enhanced US immediately after RFA to assess the ablated area, which generally extends 3-5 mm beyond the tumor edge, to ensure a safe margin and confirm complete ablation [28]. After the procedure, patients are monitored for 1 to 2 hours in the hospital. Any complications that arise during or immediately following ablation are carefully evaluated based on the patient’s clinical signs and symptoms [29].

Several distinctions exist between the RFA procedures for primary PTC and those for recurrence or metastatic LNs. First, the needle insertion pathways differ. For primary PTC, ablations typically employ the trans-isthmic approach, which enables the operator to maintain a stable electrode position, monitor the proximity of the active tip to the recurrent laryngeal nerve, and prevent the leakage of heated ablated material into the perithyroidal area [4]. In contrast, for LNs, the needle insertion path is chosen based on the LN location. Second, differences exist between liquid isolation methods. Ablations for primary PTC involve the creation of a protective barrier between the thyroid tumor and critical structures, whereas for LNs, the barrier is formed around the LN itself. Finally, the ablation techniques themselves vary. For primary PTC, the choice of either the fixed approach or the moving-shot technique is determined based on the tumor size, with the goal of ensuring a safe margin of greater than 3 mm. In contrast, ablations for LNs, which are typically smaller, generally involve a fixed ablation technique to ensure complete eradication.

Assessment of Ablation Efficacy

The effectiveness of RFA is evaluated by examining both primary and secondary endpoints, as well as the technical success of the procedure. The primary endpoint is the disease progression rate (encompassing local recurrence, the development of new tumors, LN metastasis, distant metastasis, or death due to PTC). The secondary endpoints include changes in tumor size and volume, tumor disappearance, technical success, duration of procedure, length of hospital stay, costs associated with hospitalization, and postoperative quality of life. Technical success is defined as the complete absence of enhancement on contrast-enhanced US at the conclusion of the procedure [8].

Complications are documented to assess the safety of RFA. Serious complications include thermal injury to surrounding structures (including the major vessels, esophagus, trachea, brachial plexus, or sympathetic chain), significant hematoma formation, and hemorrhage [30]. The most frequent complications include a sensation of heat during the procedure, as well as pain or discomfort during or after treatment [15]. Vocal changes due to thermal injury to the ipsilateral recurrent laryngeal nerve represent another common and clinically significant complication [31].

RFA for Primary PTC

Single Low-Risk Papillary Thyroid Microcarcinoma

Papillary thyroid microcarcinoma (PTMC) is defined as a PTC with a lesion measuring 10 mm or less in diameter. Dupuy et al. [32] first reported the use of US-guided RFA for thyroid cancer in 2001. Over the course of more than 20 years of ongoing research and advancement, numerous high-quality studies, including investigations with large cohorts and extended follow-up periods (Table 1) [25,33-35], have confirmed the clinical efficacy of RFA for treating single low-risk PTMC. This pertains to cases without clinical evidence of extrathyroidal extension, LN metastasis, or distant metastasis, and without an aggressive histological subtype.

Summary of the literature on RFA for single low-risk PTMCs

A recent review [27] reported that RFA for low-risk PTMC yields tumor volume reduction rates of 98.5% to 100%, complete disappearance rates ranging from 33.7% to 100%, and tumor progression or recurrence rates between 0% and 4.5%. Two systematic reviews and meta-analyses [15,36], as well as a large-scale matching study [37], revealed no significant differences in postoperative outcomes between RFA and surgery in the treatment of single low-risk PTMC. These outcomes included local tumor progression, LN metastasis, salvage surgery, and recurrence-free survival. However, the rate of complications was significantly higher following surgery than after RFA. Furthermore, RFA has been shown to be significantly superior to surgery in terms of hospitalization costs, length of hospital stay, duration of the procedure, volume of bleeding, and postoperative quality of life [38,39]. It also does not negatively impact subsequent surgical treatments [40]. Collectively, these findings suggest that RFA is a safe and effective treatment for low-risk PTMC and, compared to surgery, may offer a more cost-effective alternative for patients with PTMC who are ineligible for or decline surgery and AS. Nevertheless, it is important to note that most large-scale studies have been conducted in Asia, with relatively few investigations carried out in Western countries.

Multiple Low-Risk PTMCs

According to current guidelines, thermal ablation of thyroid cancer is only indicated for single low-risk PTMC; however, a growing body of research has examined the clinical outcomes of radical RFA for various other PTC types (Table 2) [9,41,42]. These studies, which include cases of bilateral and multiple PTMCs, have yielded encouraging results. Nonetheless, the sample sizes in these investigations were relatively small, and a need exists for large-scale research with long-term follow-up periods to confirm the safety and efficacy of this approach.

Summary of the literature on RFA for bilateral and multifocal low-risk PTMCs

PTCs Exceeding 1 cm

For patients with larger PTCs that do not involve LN metastasis, specifically those classified as T1bN0M0 or T2N0M0, the 2015 American Thyroid Association guidelines [10] recommend lobectomy with isthmic resection rather than total thyroidectomy. Shifts in the guidelines reflect a preference for conservative treatment. Recent research (Table 3) [43-46] indicates that RFA treatment of T1bN0M0 and T2N0M0 PTC may yield outcomes comparable to those for T1aN0M0 PTC. This could be due to the relatively indolent nature of PTC and the similar prognoses for T1a, T1b, and T2 tumors. Therefore, RFA may be a viable alternative treatment option for patients with large PTCs.

Summary of the literature on RFA for large PTCs

RFA for Recurrent and Metastatic PTC

Studies have shown [47-49] that between 10.0% and 30.0% of patients with highly differentiated thyroid cancer experience local recurrence and metastasis following surgical treatment. The anatomical alterations and fibrosis resulting from postoperative scar tissue can impede reoperation and increase the risk of complications. Consequently, current guidelines [4-7] advocate the use of thermal ablation for the radical or palliative treatment of recurrent or metastatic PTC.

Curative Ablation for Locally Recurrent Thyroid Cancer

The European 2021 guidelines [6] for the curative ablation of locally recurrent thyroid cancer indicate that radical ablation is feasible in cases involving three or fewer recurrent PTCs in the neck, each with a diameter of less than 2 cm, and in the absence of distant metastasis. A meta-analysis [50] assessing the efficacy and safety of RFA for locally recurrent and metastatic PTCs reported a tumor volume reduction rate of between 89.5% and 100%, a complete disappearance rate of 68.8%, and an average of only 1.3 ablation sessions required, suggesting the suitability of this approach for patients who are ineligible for or decline surgery. Kim et al. [51] observed no significant differences in 3-year recurrence-free survival rates between RFA and reoperation for locally recurrent PTCs smaller than 2 cm. Furthermore, a recent meta-analysis [52] confirmed that thermal ablation is a safe and effective approach for treating locally recurrent and metastatic PTCs; however, major complications, such as nerve injury, have been reported in up to 12% of cases, particularly when the recurrent foci are in the central neck region. Thus, caution should be exercised before proceeding with ablation of recurrent tumors in the central neck region.

In addition to considering structural changes, it is crucial to evaluate the biochemical response following RFA treatment for recurrent and metastatic PTCs. Serum thyroglobulin (Tg) levels are a sensitive marker for predicting the recurrence and metastasis of thyroid cancer. Moreover, they can serve as an effective indicator of the success of ablation treatment [3,6,53,54]. It is also necessary to account for the influence of anti-Tg antibodies on Tg measurements. Typically, anti-Tg antibody levels transiently rise after surgery as part of an immune response to the procedure, which often results in the underestimation of serum Tg levels in immunometric assays [4].

Palliative Ablation for Recurrent Thyroid Cancer

In cases of recurrent metastatic thyroid cancer that involves invasion of critical structures or presents cosmetic concerns, reducing tumor volume is essential to alleviate symptoms and improve quality of life [55]. To address these conditions, the American Thyroid Association guidelines recommend management strategies that include reoperation, AS, iodine-131 therapy for disease responsive to radioactive iodine, external beam radiation therapy, and various other nonsurgical modalities [56]. Palliative RFA is one example of such a modality. Furthermore, US-guided RFA in conjunction with iodine-125 seed implantation may represent an effective treatment for challenging and severe cases.

Chung et al. [57] reported the efficacy of RFA for the treatment of recurrent thyroid cancer in the central neck area following surgery. They categorized the spatial relationship of all lesions to the trachea, finding that tumors without tracheal invasion had the highest rate of complete disappearance (85.0%). This rate decreased progressively for tumors forming acute, right, and obtuse angles with the trachea, with the lowest rate observed in cases of intraluminal tracheal infiltration. The study reported a relatively high total complication rate of 21.4%, which may be due to the inclusion of tumors close to key cervical structures. Nevertheless, no life-threatening complications or sequelae arose during the follow-up period. Since the therapeutic effectiveness of RFA is inversely related to the extent of tracheal invasion by the tumor, early RFA treatment is advised for recurrent tumors in the central neck region.

US-guided RFA in conjunction with iodine-125 particle implantation frequently improves the local control of metastasis. For challenging and severe cases, including those with lesions protruding from the skin or rupture, this method offers safe and reliable treatment with high clinical utility. Zhai et al. [58] found that US-guided RFA combined with iodine-125 implantation could safely and effectively control local metastatic tumors, while also improving patients’ quality of life. These findings demonstrate the utility of palliative RFA in the management of recurrent and metastatic PTC.

Future Directions

In summary, multiple studies have confirmed the safety and effectiveness of RFA for PTC. Nevertheless, additional research is warranted to improve the detection of occult cervical LN metastases, to more accurately evaluate the aggressiveness of PTC, and to advance ablation technologies.

Diagnosis of Occult Cervical LN Metastasis

Metastasis to cervical LNs is a frequent occurrence in PTC; however, the detection of small metastatic LNs on US presents a diagnostic challenge. Several clinical studies have indicated that contrast-enhanced US may facilitate the early diagnosis of LN metastasis in PTC. Xiao et al. [59] found that the isoenhancement pattern on post-vascular contrast-enhanced US with perfluorobutane was effective in identifying small (short axis diameter, ≤8 mm) cervical lateral LNs with suspected PTC. Zhang et al. [60] reported that contrast-enhanced US lymphography provided a superior diagnostic performance to conventional B-mode US, particularly for LN metastases smaller than 1 cm and for central cervical LN metastases. Accordingly, contrast-enhanced US may represent a new approach for the early detection of LN metastasis in PTC.

Accurate Assessment of the Aggressiveness of PTC

Given the prognostic heterogeneity of PTC, a preoperative determination of its aggressiveness is essential for tailoring treatment to enhance patient prognosis and quality of life. RFA treatment may be suitable for PTCs characterized by low aggressiveness. PTC includes 13 histopathological subtypes; of these, the most aggressive are the tall cell, columnar cell, and hobnail variants, which exhibit unique clinical, pathological, and molecular characteristics [48]. RFA is not recommended for treating these aggressive subtypes. The combined analysis of molecular markers—such as the BRAF, RAS, TERT promoter, RET, and TP53 genes, along with the fusion genes RET/PTC, PAX8/PPARG, and NTRK [61-63]—in conjunction with the application of artificial intelligence [64] may facilitate the accurate evaluation of the aggressiveness, prognostic implications, and recurrence risk of PTC.

New Technologies for Minimally Invasive Therapy

The thyroid gland is surrounded by a complex array of critical structures, including the carotid artery, trachea, esophagus, and nerves. This proximity increases the potential for RFA-induced damage. Consequently, new ablation techniques should be explored and applied. Irreversible electroporation [65] employs high-voltage direct current to generate a strong electric field; this induces the formation of permanent nanoscale fissures in the cell membrane, with subsequent apoptosis and tumor necrosis. This method differs from thermal ablation in that it does not generate heat, thereby preserving tissues that are devoid of cellular components, such as blood vessels and nerves. Clinical studies have confirmed the treatment utility of irreversible electroporation for liver and pancreatic cancers, suggesting that it may represent a viable ablation option, potentially with fewer associated complications than thyroid cancer surgery.

Clear visualization of the target lesion is essential for US-guided RFA. However, US cannot penetrate the bone tissue, compromising the visibility of posterior sternal lesions and key tissue structures. US-CT fusion imaging enables the visualization of lesions that are otherwise obscured by bone tissue. Orlandi et al. [66] first validated the feasibility of RFA in the treatment of large benign thyroid nodules situated behind the sternum, employing US-CT fusion imaging in conjunction with a real-time virtual needle tracking system. This represents a potential alternative approach for the RFA treatment of recurrent and metastatic PTCs located behind the sternum.

High-Level Evidence

Although RFA treatment of PTC has yielded favorable outcomes, most previous studies have been retrospective in nature, with a scarcity of prospective research. Additionally, the literature includes no large-scale multicenter studies with long-term follow-up. With technological advances, such as innovations in cloud computing and big data, it is conceivable that a national or global data management center specifically for thyroid cancer RFA could be developed, along with a long-term follow-up mechanism. Such a center would enable the prediction and monitoring of outcomes following RFA treatment for thyroid cancer and provide robust evidence-based medical insights. This would help ensure the effectiveness of RFA in treating thyroid cancer, supported by standardized indications for its application.


US-guided RFA offers a safe and effective treatment alternative for patients with PTC who are ineligible for or decline surgery. As high-level clinical evidence continues to accumulate and technological advancements are made, the application of RFA in the treatment of PTC is expected to expand.


Author Contributions

Conceptualization: Zhao GZ, Zhang MB. Data acquisition: Zhao GZ. Data analysis or interpretation: Zhao GZ, Zhang MB. Drafting of the manuscript: Zhao GZ. Critical revision of the manuscript: Zhang MB. Approval of the final version of the manuscript: all authors.

No potential conflict of interest relevant to this article was reported.


1. Zhang M, Yan L, Li Y. Radiofrequency ablation of papillary thyroid microcarcinoma: clinical value and prospects. Chin J Med Ultrasound 2022;19:78–81.
2. Zanoni DK, Patel SG, Shah JP. Changes in the 8th edition of the American Joint Committee on Cancer (AJCC) staging of head and neck cancer: rationale and implications. Curr Oncol Rep 2019;21:52.
3. Chung SR, Baek JH, Choi YJ, Lee JH. Longer-term outcomes of radiofrequency ablation for locally recurrent papillary thyroid cancer. Eur Radiol 2019;29:4897–4903.
4. Kim JH, Baek JH, Lim HK, Ahn HS, Baek SM, Choi YJ, et al. 2017 Thyroid radiofrequency ablation guideline: Korean Society of Thyroid Radiology. Korean J Radiol 2018;19:632–655.
5. Ultrasound Society of Physicians of Chinese Medical Doctor Association. Expert consensus on indications for thermal ablation therapy of papillary thyroid microcarcinoma. Chin J Med Ultrasound 2019;16:571–574.
6. Mauri G, Hegedus L, Bandula S, Cazzato RL, Czarniecka A, Dudeck O, et al. European thyroid association and cardiovascular and Interventional Radiological Society of Europe 2021 clinical practice guideline for the use of minimally invasive treatments in malignant thyroid lesions. Eur Thyroid J 2021;10:185–197.
7. Orloff LA, Noel JE, Stack BC Jr, Russell MD, Angelos P, Baek JH, et al. Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: an international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with the Asia Pacific Society of Thyroid Surgery, Associazione Medici Endocrinologi, British Association of Endocrine and Thyroid Surgeons, European Thyroid Association, Italian Society of Endocrine Surgery Units, Korean Society of Thyroid Radiology, Latin American Thyroid Society, and Thyroid Nodules Therapies Association. Head Neck 2022;44:633–660.
8. Cao XJ, Wang SR, Che Y, Liu J, Cong ZB, He JF, et al. Efficacy and safety of thermal ablation for treatment of solitary T1N0M0 papillary thyroid carcinoma: a multicenter retrospective study. Radiology 2021;300:209–216.
9. Yan L, Zhang M, Song Q, Xie F, Luo Y. Clinical outcomes of radiofrequency ablation for multifocal papillary thyroid microcarcinoma versus unifocal papillary thyroid microcarcinoma: a propensity-matched cohort study. Eur Radiol 2022;32:1216–1226.
10. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1–133.
11. Haser GC, Tuttle RM, Su HK, Alon EE, Bergman D, Bernet V, et al. Active surveillance for papillary thyroid microcarcinoma: new challenges and opportunities for the health care system. Endocr Pract 2016;22:602–611.
12. Oh HS, Ha J, Kim HI, Kim TH, Kim WG, Lim DJ, et al. Active surveillance of low-risk papillary thyroid microcarcinoma: a multi-center cohort study in Korea. Thyroid 2018;28:1587–1594.
13. Jin M, Kim HI, Ha J, Jeon MJ, Kim WG, Lim DJ, et al. Tumor volume doubling time in active surveillance of papillary thyroid microcarcinoma: a multicenter cohort study in Korea. Thyroid 2021;31:1494–1501.
14. Chung SR, Baek JH, Choi YJ, Lee JH. Thermal ablation for the management of papillary thyroid microcarcinoma in the era of active surveillance and hemithyroidectomy. Curr Oncol Rep 2022;24:1045–1052.
15. Kim HJ, Cho SJ, Baek JH. Comparison of thermal ablation and surgery for low-risk papillary thyroid microcarcinoma: a systematic review and meta-analysis. Korean J Radiol 2021;22:1730–1741.
16. Tuttle RM, Li D, Ridouani F. Percutaneous ablation of low-risk papillary thyroid cancer. Endocr Relat Cancer 2023;30e220244.
17. Mauri G, Pacella CM, Papini E, Solbiati L, Goldberg SN, Ahmed M, et al. Image-guided thyroid ablation: proposal for standardization of terminology and reporting criteria. Thyroid 2019;29:611–618.
18. Shi L, Pang R, Li R. Research progress in radiofrequency ablation in treatment of papillary thyroid carcinoma. J Jilin Univ 2019;45:731–735.
19. Chen W, Chen B, Zhao S. Guidelines and research advances for thermal ablation of thyroid cancer. J Jiangsu Univ 2022;32:297–305.
20. Monchik JM, Donatini G, Iannuccilli J, Dupuy DE. Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. Ann Surg 2006;244:296–304.
21. Wu J, Wei Y, Zhao ZL, Peng LL, Li Y, Lu NC, et al. A preliminary study of microwave ablation for solitary T1N0M0 papillary thyroid carcinoma with capsular invasion. Int J Hyperthermia 2022;39:372–378.
22. Cao XJ, Yu MA, Zhu YL, Qi L, Cong ZB, Yan GZ, et al. Ultrasound-guided thermal ablation for papillary thyroid microcarcinoma: a multicenter retrospective study. Int J Hyperthermia 2021;38:916–922.
23. Ge MH, Xu D, Yang AK, Cheng RC, Sun H, Wang HC, et al. Expert consensus on thermal ablation for thyroid benign nodes, microcarcinoma and metastatic cervical lymph nodes (2018 edition). China Cancer 2018;27:768–773.
24. Li JR, Luo YK. Application of radiofrequency ablation technology in treatment of thyroid nodules. Acad J Chin PLA Med Sch 2016;37:807–809.
25. Zhang M, Luo Y, Zhang Y, Tang J. Efficacy and safety of ultrasound-guided radiofrequency ablation for treating low-risk papillary thyroid microcarcinoma: a prospective study. Thyroid 2016;26:1581–1587.
26. Zhang M, Tufano RP, Russell JO, Zhang Y, Zhang Y, Qiao Z, et al. Ultrasound-guided radiofrequency ablation versus surgery for low-risk papillary thyroid microcarcinoma: results of over 5 years' follow-up. Thyroid 2020;30:408–417.
27. Ntelis S, Linos D. Efficacy and safety of radiofrequency ablation in the treatment of low-risk papillary thyroid carcinoma: a review. Hormones (Athens) 2021;20:269–277.
28. Yan Y, Lin J, Gao Z. Preliminary study on the range of thermal ablation of 144 cases with thyroid micropapillary carcinoma. J Chin Oncol 2019;25:924–925.
29. Yan L, Luo Y, Zhang Y, Zhu Y, Xiao J, Lan Y, et al. The clinical application of core-needle biopsy after radiofrequency ablation for low-risk papillary thyroid microcarcinoma: a large cohort of 202 patients study. J Cancer 2020;11:5257–5263.
30. Baldwin CK, Natter MB, Patel KN, Hodak SP. Minimally invasive techniques for the management of thyroid nodules. Endocrinol Metab Clin North Am 2022;51:323–349.
31. Ou D, Chen C, Jiang T, Xu D. Research review of thermal ablation in the treatment of papillary thyroid carcinoma. Front Oncol 2022;12:859396.
32. Dupuy DE, Monchik JM, Decrea C, Pisharodi L. Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy. Surgery 2001;130:971–977.
33. Song Q, Gao H, Tian X, Ren L, Lan Y, Yan L, et al. Evaluation of ultrasound-guided radiofrequency ablation as a treatment option for papillary thyroid microcarcinoma in the isthmus: a retrospective study. Front Endocrinol (Lausanne) 2020;11:599471.
34. Yan L, Lan Y, Xiao J, Lin L, Jiang B, Luo Y. Long-term outcomes of radiofrequency ablation for unifocal low-risk papillary thyroid microcarcinoma: a large cohort study of 414 patients. Eur Radiol 2021;31:685–694.
35. Seo YK, Cho SW, Sim JS, Yang GE, Cho W. Radiofrequency ablation of papillary thyroid microcarcinoma: a 10-year follow-up study. J Korean Soc Radiol 2021;82:914–922.
36. Sun YD, Zhang H, Zhu HT, Wu CX, Chen ML, Han JJ. A systematic review and meta-analysis comparing tumor progression and complications between radiofrequency ablation and thyroidectomy for papillary thyroid carcinoma. Front Oncol 2022;12:994728.
37. Yan L, Zhang M, Song Q, Luo Y. Ultrasound-guided radiofrequency ablation versus thyroid lobectomy for low-risk papillary thyroid microcarcinoma: a propensity-matched cohort study of 884 patients. Thyroid 2021;31:1662–1672.
38. Chen S, Mao Y, Chen G. Economic effect between surgery and thermal ablation for patients with papillary thyroid microcarcinoma: a systemic review and meta-analysis. Endocrine 2022;76:9–17.
39. Lan Y, Luo Y, Zhang M, Jin Z, Xiao J, Yan L, et al. Quality of life in papillary thyroid microcarcinoma patients undergoing radiofrequency ablation or surgery: a comparative study. Front Endocrinol (Lausanne) 2020;11:249.
40. Li X, Li J, Qiao Z, Yan L, Xiao J, Li Y, et al. Rigorous radiofrequency ablation can completely treat low-risk small papillary thyroid carcinoma without affecting subsequent surgical management. Eur Radiol 2023;33:4189–4197.
41. Yan L, Zhang M, Song Q, Xiao J, Zhang Y, Luo Y. The efficacy and safety of radiofrequency ablation for bilateral papillary thyroid microcarcinoma. Front Endocrinol (Lausanne) 2021;12:663636.
42. Yan L, Yang Z, Li Y, Li X, Xiao J, Jing H, et al. Five-year outcome between radiofrequency ablation vs surgery for unilateral multifocal papillary thyroid microcarcinoma. J Clin Endocrinol Metab 2023;108:3230–3238.
43. Xiao J, Zhang Y, Zhang M, Lan Y, Yan L, Luo Y, et al. Ultrasonography-guided radiofrequency ablation vs. surgery for the treatment of solitary T1bN0M0 papillary thyroid carcinoma: a comparative study. Clin Endocrinol (Oxf) 2021;94:684–691.
44. He H, Wu R, Zhao J, Song Q, Zhang Y, Luo Y. Ultrasound-guided radiofrequency ablation versus surgical resection for the treatment of T1bN0M0 papillary thyroid carcinoma in different age groups. Front Endocrinol (Lausanne) 2021;12:734432.
45. Yan L, Li X, Li Y, Xiao J, Zhang M, Luo Y. Comparison of ultrasound-guided radiofrequency ablation versus thyroid lobectomy for T1bN0M0 papillary thyroid carcinoma. Eur Radiol 2023;33:730–740.
46. Xiao J, Zhang Y, Zhang M, Xie F, Yan L, Luo Y, et al. Ultrasonography-guided radiofrequency ablation for the treatment of T2N0M0 papillary thyroid carcinoma: a preliminary study. Int J Hyperthermia 2021;38:402–408.
47. Cavalheiro BG, Shah JP, Randolph GW, Medina JE, Tufano RP, Zafereo M, et al. Management of recurrent well-differentiated thyroid carcinoma in the neck: a comprehensive review. Cancers (Basel) 2023;15:923.
48. Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr Pathol 2022;33:27–63.
49. Shi Y, Yang Z, Heng Y, Ju H, Pan Y, Zhang Y. Clinicopathological findings associated with cervical lymph node metastasis in papillary thyroid microcarcinoma: a retrospective study in China. Cancer Control 2022;29:10732748221084926.
50. Suh CH, Baek JH, Choi YJ, Lee JH. Efficacy and safety of radiofrequency and ethanol ablation for treating locally recurrent thyroid cancer: a systematic review and meta-analysis. Thyroid 2016;26:420–428.
51. Kim JH, Yoo WS, Park YJ, Park DJ, Yun TJ, Choi SH, et al. Efficacy and safety of radiofrequency ablation for treatment of locally recurrent thyroid cancers smaller than 2 cm. Radiology 2015;276:909–918.
52. Zhang X, Ni T, Zhang W. Ultrasonography-guided thermal ablation for cervical lymph node metastasis of recurrent papillary thyroid carcinoma: is it superior to surgical resection? Front Endocrinol (Lausanne) 2022;13:907195.
53. Zhou W, Chen Y, Zhang L, Ni X, Xu S, Zhan W. Percutaneous microwave ablation of metastatic lymph nodes from papillary thyroid carcinoma: preliminary results. World J Surg 2019;43:1029–1037.
54. Chen WC, Chou CK, Chang YH, Chiang PL, Lim LS, Chi SY, et al. Efficacy of radiofrequency ablation for metastatic papillary thyroid cancer with and without initial biochemical complete status. Front Endocrinol (Lausanne) 2022;13:933931.
55. Jeong SY, Baek JH, Choi YJ, Lee JH. Ethanol and thermal ablation for malignant thyroid tumours. Int J Hyperthermia 2017;33:938–945.
56. Sun W, Di L, Chen L, Li D, Wu Y, Xiang J, et al. The outcomes and prognostic factors of patients who underwent reoperation for persistent/recurrent papillary thyroid carcinoma. BMC Surg 2022;22:374.
57. Chung SR, Baek JH, Choi YJ, Sung TY, Song DE, Kim TY, et al. Efficacy of radiofrequency ablation for recurrent thyroid cancer invading the airways. Eur Radiol 2021;31:2153–2160.
58. Zhai Y, Shao Y, Li Q. Case report: a case of radioactive iodinerefractory thyroid cancer accompanying cervical lymph node metastasis treated with US-guided RFA combined with (125)I seed implantation. Front Oncol 2022;12:987484.
59. Xiao L, Zhou J, Tan W, Liu Y, Zheng H, Wang G, et al. Contrast-enhanced US with perfluorobutane to diagnose small lateral cervical lymph node metastases of papillary thyroid carcinoma. Radiology 2023;307e221465.
60. Zhang Y, Lu YY, Li W, Zhao JH, Zhang Y, He HY, et al. Lymphatic contrast-enhanced US to improve the diagnosis of cervical lymph node metastasis from thyroid cancer. Radiology 2023;307e221265.
61. Patel J, Klopper J, Cottrill EE. Molecular diagnostics in the evaluation of thyroid nodules: current use and prospective opportunities. Front Endocrinol (Lausanne) 2023;14:1101410.
62. Yang X. Research progress of thyroid cancer molecular markers. J Clin Pathol Res 2015;35:1148–1156.
63. Fang J, Yang F. Assessment of aggressiveness in thyroid papillary microcarcinoma. Chin Arch Otolaryngol-Head Neck Surg 2018;25:403–405.
64. Li L, Du B, Chen C. Progress of artificial intelligence for precision medicine in thyroid cancer. Chin J Clin Oncol 2020;47:369–374.
65. Yuan J, Yang L, Huang X. Research progress of irreversible electroporation in tumor ablation. J Reg Anat Op Surg 2018;27:920–924.
66. Orlandi D, Viglino U, Dedone G, Leale G, Caruso P, Mauri G, et al. US-CT fusion-guided percutaneous radiofrequency ablation of large substernal benign thyroid nodules. Int J Hyperthermia 2022;39:847–854.

Article information Continued


Key point

Ultrasound-guided thermal ablation represents a safe and effective treatment alternative for patients with papillary thyroid carcinoma who are ineligible for or decline surgery.

Table 1.

Summary of the literature on RFA for single low-risk PTMCs

Source Country Research perspective Follow-up (month) No. of patients Volume reduction rate (%) Complete disappearance rate (%) Adverse reactions Recurrence
Song et al. (2020) [33] China Large sample 30.2±13.9 112 100 100 0 PTMC (1/112, 0.9%)
Yan et al. (2021) [34] China Large sample 42.1±11.9 414 98.8 88.4 0 PTMC (10/414, 2.4%)
Zhang et al. (2016) [25] China Long-term follow-up 64.2±2.8 92 NA NA 0 PTMC (1/92, 1.1%)
Seo et al. (2021) [35] Korea Long-term follow-up 130.6 (121-159) 5 NA 60 0 0

RFA, radiofrequency ablation; PTMC, papillary thyroid microcarcinoma; NA, not applicable.

Table 2.

Summary of the literature on RFA for bilateral and multifocal low-risk PTMCs

Source Country Research perspective Follow-up (month) No. of patients Volume reduction rate (%) Complete disappearance rate (%) Adverse reactions Recurrence
Yan et al. (2021) [41] China Bilateral PTMCs 44.8±11.5 47 99.9 92.0 Localized pain (4/47, 8.5%) PTMC (2/47, 4.3%)
Yan et al. (2022) [9] China Multifocal PTMCs 47.9±11.4 55 99.9 95.6 Localized pain (3/55, 5.4%) PTMC (1/55, 1.8%)
Yan et al. (2023) [42] China Multifocal PTMCs 72.9 44 NA 95.5 0 LN metastasis (1/44, 2.3%), persistent lesion (1/44, 2.3%)

RFA, radiofrequency ablation; PTMC, papillary thyroid microcarcinoma; NA, not applicable; LN, lymph node.

Table 3.

Summary of the literature on RFA for large PTCs

Source Country Research perspective Follow-up (month) No. of patients Volume reduction rate (%) Complete disappearance rate (%) Adverse reactions Recurrence
Xiao et al. (2021) [43] China T1bN0M0 PTCs 26±10.3 91 99.0 NA Localized pain (2/91, 2.2%) PTMC (3/91, 3.3%)
He et al. (2021) [44] China T1bN0M0 PTCs 36 94 99.9 NA Moderate fever (1/94, 1.1%), hoarseness (1/94, 1.1%) PTMC (4/94, 4.3%)
Yan et al. (2023) [45] China T1bN0M0 PTCs 50.4 91 NA 74.7 0 PTMC (2/91, 2.2%)
Xiao et al. (2021) [46] China T2N0M0 PTCs 24.1±6.9 12 93.7 16.7 0 0

RFA, radiofrequency ablation; PTC, papillary thyroid carcinoma; NA, not applicable; PTMC, papillary thyroid microcarcinoma.